{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:07:26Z","timestamp":1783937246892,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) raise hemoglobin in patients with heart failure (HF). We characterized the prevalence, dynamics, predictors and prognostic implications of three hemoglobin states (anemia, normal, and erythrocytosis) at baseline and during the first year on SGLT2i therapy. Methods: Prospective single-center registry of 1244 HF patients with a baseline hemoglobin who initiated dapagliflozin or empagliflozin (March 2022\u2013October 2025). Hemoglobin was categorized at baseline, 6 and 12 months using WHO sex-specific thresholds. We analyzed inter-category transitions, predictors of each hemoglobin category at each timepoint, time-to-event outcomes (all-cause death, MACE, thrombosis) in landmark analyses, and the correlation of hemoglobin change with concurrent changes in left ventricular ejection fraction and NT-proBNP. Results: At baseline, 23.6% had anemia, 71.1% were normal, and 5.3% had erythrocytosis. The prevalence of erythrocytosis remained low throughout, with a modest, transient rise to 8.0% at 6 months before returning toward baseline (5.9% at 12 months), even though the underlying composition of patients was highly dynamic. Among baseline-normal patients, downward transition to anemia (7.8% at 6 months, 9.2% at 12 months) occurred at rates equal to or greater than upward transition to erythrocytosis (7.7% and 6.0%, respectively). The prevalence of anemia decreased significantly between baseline and the follow-up timepoints. Across timepoints, the patient\u2019s own baseline hemoglobin was the dominant independent predictor of both subsequent erythrocytosis and subsequent anemia. Other independent predictors of erythrocytosis were higher adherence to SGLT2i, male sex, current smoking, COPD or asthma, higher heart rate and lower serum albumin. Other independent predictors of anemia were non-adherence to or discontinuation of SGLT2i, peripheral arterial disease, advanced age, diabetes, lower eGFR, higher NT-proBNP and lower serum albumin. Increases in hemoglobin from baseline were associated with greater concurrent reductions in NT-proBNP at 6 and 12 months but were not associated with changes in LVEF at either timepoint. Anemia was independently associated with all-cause death at the baseline and 6-month landmarks (adjusted HRs are 2.23 and 2.45, respectively; time-varying HR is 2.55), with a consistent but non-significant point estimate at 12 months (aHR of 1.90), and with significant 6-month MACE estimate (aHR of 3.07). Erythrocytosis was not associated with mortality, MACE or thrombosis at any timepoint, although the small number of patients and thrombotic events limits interpretation. Dapagliflozin and empagliflozin were associated with indistinguishable hemoglobin trajectories. Conclusions: On SGLT2i therapy, anemia carries the dominant prognostic signal and identifies a high-risk subgroup; erythrocytosis is uncommon, transient and showed no detectable association with adverse outcomes, though thrombotic events were too few for firm safety conclusions. Routine monitoring of hemoglobin for anemia is of higher clinical importance compared to erythrocytosis; these single-center findings require external validation.<\/jats:p>","DOI":"10.3390\/jcm15145465","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:53:58Z","timestamp":1783932838000},"page":"5465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemoglobin Trajectories on SGLT2 Inhibitor Therapy in Heart Failure: Anemia Marks Adverse Prognosis While Erythrocytosis Is Transient and Not Associated with Adverse Outcomes"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-9691","authenticated-orcid":false,"given":"Ivana","family":"Jurin","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-9134","authenticated-orcid":false,"given":"Irzal","family":"Had\u017eibegovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"Faculty of Dental Medicine and Health Care, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-2774","authenticated-orcid":false,"given":"Marin","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6323-3114","authenticated-orcid":false,"given":"Matea","family":"Marovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"\u010cikara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijani\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"Scientific Research and Translational Medicine Department, University Hospital Dubrava, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"dgaa057","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.amjcard.2025.09.011","article-title":"Secondary Erythrocytosis in Patients with Heart Failure on SGLT2 Inhibitors: Insights from a Multicenter \u201cReal World\u201d Study","volume":"259","author":"Pherai","year":"2026","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e010613","DOI":"10.1161\/CIRCHEARTFAILURE.123.010613","article-title":"SGLT2 Inhibitor-Related Polycythemia in a Patient with Chronic Heart Failure: A Potential Severe Adverse Event","volume":"16","author":"Tukker","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107729","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Heerspink","year":"2020","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: A post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2517086","DOI":"10.1001\/jamanetworkopen.2025.17086","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults with Type 2 Diabetes","volume":"8","author":"Lewis","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood.2021013996","article-title":"JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy","volume":"138","author":"Gangat","year":"2021","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/joim.13722","article-title":"Sodium-glucose cotransporter-2 inhibitor-associated erythrocytosis: A retrospective cohort study","volume":"295","author":"Liu","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s11606-024-08640-x","article-title":"Association Between SGLT2 Inhibitor Use and Change in Hemoglobin Among Adults with Diabetes: A Nationwide Cohort Study","volume":"39","author":"Lassen","year":"2024","journal-title":"J. Gen. Intern. Med."},{"key":"ref_21","first-page":"E165","article-title":"Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases","volume":"98","author":"Gangat","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1182\/bloodadvances.2025016320","article-title":"Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females","volume":"9","author":"Doi","year":"2025","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/bloodadvances.2024015410","article-title":"Diagnosis, management, and outcomes of drug-induced erythrocytosis: A systematic review","volume":"9","author":"Liu","year":"2025","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"World Medical Association (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J. Am. Med. Assoc., 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moon, S.J., Lee, W.Y., Hwang, J.S., Hong, Y.P., and Morisky, D.E. (2017). Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187139"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.seminhematol.2015.07.006","article-title":"Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change with Aging?","volume":"52","author":"Cappellini","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_27","first-page":"47","article-title":"Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients","volume":"209","author":"Holik","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/00365513.2024.2321589","article-title":"Secondary polycythemia in acutely ill COVID-19 patients is associated with higher mortality but not markedly higher thrombotic risk","volume":"84","author":"Vasilj","year":"2024","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: Competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/hematology.2025000704","article-title":"JAK2 wild-type erythrocytosis: Concept, differential diagnosis, diagnostic steps, and treatment approaches","volume":"2025","author":"Szuber","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41375-021-01290-6","article-title":"JAK2 unmutated erythrocytosis: Current diagnostic approach and therapeutic views","volume":"35","author":"Gangat","year":"2021","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/bloodadvances.2025016967","article-title":"SGLT2i-associated erythrocytosis: Closing the evidence gap","volume":"9","author":"Hsia","year":"2025","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3325\/cmj.2025.66.135","article-title":"Dapagliflozin vs. empagliflozin in patients with chronic heart failure: A registry analysis","volume":"66","author":"Jurin","year":"2025","journal-title":"Croat. Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jurin, I., Ivanovi\u0107 Mihajlovi\u0107, V., \u0160aki\u0107, Z., Pavlov, M., \u0160ipi\u0107, T., Vitlov, P., Falak, H., Grizelj, D., Manola, \u0160., and Udovi\u010di\u0107, M. (2024). Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11110364"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lekovic, D., Sobas, M., and Lucijanic, M. (2025). Editorial: Differential diagnosis of erythrocytosis and analysis of their clinical utility. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1742762"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and Cause of Death in Patients Diagnosed with Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Stuckey, R., and G\u00f3mez-Casares, M.T. (2021). Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095042"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Krecak, I., Krecak, M.V., Marketin, T., Marcinkovic, M., Holik, H., Skelin, M., Budimir, J., Lucijanic, M., and Klobucar, S. (2026). Differentiating polycythemia vera from sodium-glucose cotransporter 2 inhibitor-associated polycythemia. Acta Diabetol.","DOI":"10.1007\/s00592-026-02651-2"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:13:23Z","timestamp":1783934003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":43,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145465"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145465","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}